HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers

Status: Recruiting
Location: See all (9) locations...
Intervention Type: Other, Procedure, Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer. IMPT is a type of radiation therapy that allows for the most accurate application of proton radiation to the tumor and has the potential to reduce treatment-related side effects. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of x-ray radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. IMPT may work as well as IMRT after surgery in treating patients with head and neck cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \>= 18 years

• Histological confirmation of a newly diagnosed non-human papillomavirus (HPV) associated malignant epithelial cancer in the head and/or neck. Diagnosis requires confirmation of p16 and/or HPV DNA negativity for oropharyngeal and unknown primary sites. p16 positivity in skin cancers is allowed

• Primary lesion located in the nasal cavity, paranasal sinuses, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, lymph nodes (unknown primary or metastasis from head and neck \[HN\]-skin primary) or skin cancer where lymph node radiation is recommended

⁃ NOTE: Patients with primary lesions in the larynx must have a T3 primary, bulky T2 primary (\> 6 cc), and/or at least 1 regional lymph node

• Confirmation of American Joint Committee on Cancer (AJCC) 8th edition defined M0 established by positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI)

• Eastern Cooperative Oncology Group (ECOG) performance status (0-1 prior to initial treatment)

• Able to provide written informed consent

• Able to complete questionnaires independently or with assistance

• Willing to return to enrolling institution for follow up during the observation phase

Locations
United States
Arizona
Mayo Clinic Hospital in Arizona
RECRUITING
Phoenix
Mayo Clinic in Arizona
RECRUITING
Scottsdale
Florida
Mayo Clinic in Florida
RECRUITING
Jacksonville
Minnesota
Mayo Clinic Health System in Albert Lea
RECRUITING
Albert Lea
Mayo Clinic Health System - Mankato
RECRUITING
Mankato
Mayo Clinic Radiation Therapy - Northfield
RECRUITING
Northfield
Mayo Clinic in Rochester
RECRUITING
Rochester
Wisconsin
Mayo Clinic Health System - Eau Claire
RECRUITING
Eau Claire
Mayo Clinic Health System - Franciscan Healthcare
RECRUITING
La Crosse
Contact Information
Primary
Clinical Trials Referral Office
mayocliniccancerstudies@mayo.edu
855-776-0015
Time Frame
Start Date: 2022-02-16
Estimated Completion Date: 2035-11-15
Participants
Target number of participants: 174
Treatments
Experimental: Arm A (IMPT, IMRT, cisplatin)
Patients undergo IMPT or IMRT for 18 sessions over 24 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
Experimental: Arm B (IMPT, cisplatin)
Patients undergo IMPT for 15 sessions over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
Experimental: Arm C (IMRT, cisplatin)
Patients undergo IMRT for 15 sessions over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care. Patients undergo CT or MRI and PET/CT or PET/MRI during screening and follow-up. Patients may also undergo blood sample collection throughout the trial.
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov